[ 11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: Comparison with bone scintigraphy

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 1, 2012, Pages 13-26

  Picchio, Maria ^a,b   Spinapolice, Elena Giulia ^c   Fallanca, Federico ^a   Crivellaro, Cinzia ^c   Giovacchini, Giampiero ^c,d   Gianolli, Luigi ^a   Messa, Cristina ^b,c,e  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e SAN GERARDO HOSPITAL   (Italy)

Author keywords

11C choline; Bone metastases; Bone scintigraphy; PET CT; Positron emission tomography; Prostate cancer recurrence

Indexed keywords

ANTIANDROGEN; CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BIOCHEMICAL COMPOSITION; BONE METASTASIS; BONE SCINTISCANNING; CANCER GROWTH; CANCER PATIENT; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HUMAN; MALE; MORPHOLOGICAL ADAPTATION; PROSTATE CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; BLOOD; BONE; BONE TUMOR; COMPARATIVE STUDY; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SCINTISCANNING;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; CARBON RADIOISOTOPES; CHOLINE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84858754689     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1920-z     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300.
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27 (3):165-76. (Pubitemid 32452017)
3. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;277(6):467-71.
4. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110(8):1860-7. (Pubitemid 47557312)
5. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169(2):517-23. (Pubitemid 36132976)
6. Fuccio C, Castellucci P, Schiavina R, Santi I, Allegri V, Pettinato V, et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 2010;24(6):485-92.
7. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61-71.
8. Damber JE, Aus G. Prostate cancer. Lancet 2008;371(9625):1710-21. (Pubitemid 351671887)
9. Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18F]fluorocholine and [18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168(1):273-80. (Pubitemid 34640843)
10. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004;171(6 Pt 1):2122-7. (Pubitemid 38625418)
11. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000;88(12 Suppl):2989-94. (Pubitemid 30413181)
12. Rudoni M, Antonini G, Favro M, Baroli A, Brambilla M, Cardani G, et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995;22(3):207-11.
13. Cher ML, Bianco FJ, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160(4):1387-91. (Pubitemid 29480523)
14. Jacobson AF, Fogelman I. Bone scanning in clinical oncology: does it have a future? Eur J Nucl Med 1998;25(9):1219-23. (Pubitemid 28446045)
15. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59(4):572-83.
16. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37(1):181-200.
17. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243(1):28-53. (Pubitemid 46579693)
18. Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009;39(6):396-407.
19. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32(11):1253-8. (Pubitemid 41598715)
20. Picchio M, Crivellaro C, Giovacchini G, Gianolli L, Messa C. PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging 2009;53(2):245-68.
21. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/ computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 2011;59:51-60.
22. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008;35(10):1766-74.
23. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169(4):1337-40. (Pubitemid 36323779)
24. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34(4):274-92. (Pubitemid 39365998)
25. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37(2):301-9.
26. Picchio M, Landoni C, Messa C, Gianolli L, Matarrese M, De Cobelli F, et al. Positive [11C]choline and negative [18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol 2002;179(2):482-4. (Pubitemid 34785658)
27. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/ CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009;50(9):1394-400.
28. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33(12):1387-98. (Pubitemid 44885404)
29. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47(2):287-97. (Pubitemid 46780894)
30. Du Y, Cullum I, Illidge TM, Ell PJ. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positronemission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007;25(23):3440-7. (Pubitemid 47310881)
31. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2009;11(6):446-54.
32. Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, et al. A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol 2010;10:9.
33. Giovacchini G, Picchio M, Coradeschi E, Scattoni V, Bettinardi V, Cozzarini C, et al. [(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging 2008;35(6):1065-73.
34. Fuccio C, Schiavina R, Castellucci P, Rubello D, Martorana G, Celli M, et al. Androgen deprivation therapy influences the uptake of (11)C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging 2011.